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Abstract
Background: Apolipoprotein A-V (Apo A-V) gene has recently been identified as a new
apolipoprotein involved in triglyceride metabolism. A single nucleotide polymorphism (SNP3)
located in the gene promoter (-1131) was associated with triglyceride variation in healthy subjects.
In type 2 diabetes the triglyceride level increased compared to healthy subjects.
Hypertriglyceridemia is a risk factor for coronary artery disease. We aimed to examine the
interaction between SNP3 and lipid profile and coronary artery disease (CAD) in Tunisian type 2
diabetic patients.
Results: The genotype frequencies of T/T, T/C and C/C were 0.74, 0.23 and 0.03 respectively in
non diabetic subjects, 0.71, 0.25 and 0.04 respectively in type 2 diabetic patients. Triglyceride level
was higher in heterozygous genotype (-1131 T/C) of apo A-V (p = 0.024). Heterozygous genotype
is more frequent in high triglyceride group (40.9%) than in low triglyceride group (18.8%) ; p =
0.011. Despite the relation between CAD and hypertriglyceridemia the SNP 3 was not associated
with CAD.
Conclusion: In type 2 diabetic patients SNP3 is associated with triglyceride level, however there
was no association between SNP3 and coronary artery disease.
Background
Dyslipidemia in type 2 diabetes are most frequently char-
acterized by elevation of total serum triglycerides, of very
low density lipoprotein-triglyceride (VLDL-TG) and low
level of high density lipoprotein-cholesterol (HDL-C) [1].
Hypertriglyceridemia is an independent risk factor for cor-
onary artery disease (CAD) in type 2 diabetes [2]. Triglyc-
eridemia is modulated by environmental and genetic
factors. A new identified gene associated with triglyceride
level was the gene encoding for apo A-V located at the
chromosome 11 (11q23), in the vicinity of apoA-I/C-III/
A-IV cluster [3]. Studies on transgenic mice overexpressing
human apo A-V showed a decreased level of triglyceride,
whereas knock-out mice showed an increased level of
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apo A-V on triglyceride metabolism. Moreover apo A-V
regulates levels of circulating triglyceride and cholesterol
[4]. Four neighboring single nucleotide polymorphisms
(SNP1 to SNP4) within apo A-V were identified by Penna-
chio et al [3]. The first three of the SNPs (SNPs1–3) were
in significant linkage disequilibrium suggesting the exist-
ence of a common haplotype in apo A-V gene. The minor
allele of each SNP was associated with high triglyceride
level. In other study, the SNP3 (T/C polymorphism) was
also associated with HDL-C concentration [5]. This sug-
gests that genetic variability of the apo A-V gene is likely
to also have an impact on the lipid profile of type 2 dia-
betic patients, but reports on the subjects are few [6].
We have addressed the issue to examine the interaction
between SNP3 and lipid profile and coronary artery dis-
ease (CAD) in type 2 diabetic patients compared to con-
trols in Tunisian population.
Results
Description of the participating groups
Type 2 diabetic patients have a BMI values more impor-
tant than non diabetic subjects. Whereas the WHR in
lower in controls. Males and smokers are more frequent in
patients with CAD (Table 1). To compare lipid parame-
ters, we take into consideration the lipid lowering drugs
use, then patients who are taking lipid lowering drugs
were excluded (Table 2). Plasma total cholesterol and
total triglyceride concentrations were significantly higher
in type 2 diabetic patients than in the non diabetic
patients. Subjects with CAD had lower concentration of
HDL-C and higher concentration of triglyceride as com-
pared to those without CAD (Table 2).
Heterozygous genotype had the high triglyceride level
According to SNP3 of the apo A-V gene, variation of lipid
parameters in diabetic or non diabetic patients are shown
in Table 3. Non diabetic subjects having the heterozygous
genotype (T/C) showed an increased triglyceride level and
decreased HDL-C concentration. However these varia-
tions were not significant. In type 2 diabetic patients, trig-











CAD vs non 
CAD
Number 99 78 74 57
Sex (% of men) 50.5 49.4 75.4 84.2 ns < 0.001
Age (years) 52.9 ± 8.7 51.5 ± 7.3 55.7 ± 6.8 59.0 ± 6.8 ns < 0.001
BMI (Kg/m2) 27.6 ± 4.0 28.8 ± 4.6 28.1 ± 3.8 26.6 ± 4.8 0.029 ns
Smokers (%) 42 53 86 80 0.003 < 0.001
SBP (mmHg) 12.5 ± 1.3 13.2 ± 1.4 13.0 ± 1.8 12.4 ± 2.1 0.001 ns
DBP (mmHg) 7.5 ± 0.7 7.8 ± 0.9 7.6 ± 1.0 7.1 ± 1.1 0.006 0.018
WHR 0.82 ± 0.09 0.92 ± 0.07 0.95 ± 0.07 0.92 ± 0.06 ns 0.016
Glucose (mmol/l) 5.2 ± 0.4 10.4 ± 3.4 11.7 ± 3.5 6.8 ± 3.6 < 0.001 < 0.001
HbA1c (%) 4.5 ± 0.9 10.4 ± 3.4 9.4 ± 2.4 11.3 ± 4.1 0.009 < 0.001
Diabetes duration (years) 6.8 ± 5.2 7.9 ± 6.1
Lipid lowering drug use (%) 11.1 0 16.2 70.2
SBP : systolic blood pressure
DBP : diastolic blood pressure











CAD vs non 
CAD
Number 88 78 62 17
Cholesterol (mmol/l) 4.70 ± 1.22 5.16 ± 1.14 5.13 ± 1.12 4.06 ± 1.22 < 0.001 ns
HDL-C (mmol/l) 0.94 ± 0.24 0.96 ± 0.38 0.79 ± 0.22 0.72 ± 0.21 ns < 0.001
Total TG (mmol/l) 1.39 ± 0.75 2.11 ± 1.48 2.27 ± 1.77 2.81 ± 2.53 < 0.001 < 0.001Page 2 of 6
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association with non significant decrease in HDL-C con-
centration. The genotype frequencies of T/T, T/C and C/C
were 0.74, 0.23 and 0.03 respectively in non diabetic sub-
jects, 0.71, 0.25 and 0.04 respectively in type 2 diabetic
patients. The SNP3 was shown to be in Hardy-Weinberg
equilibrium. It is clear that there was no difference in gen-
otype distribution between diabetic and non diabetic sub-
jects. The type 2 diabetic population was classified further
into those with high and low triglyceride concentration
(cut point 2.2 mmol/l which was more than 90 percentile
level in the healthy population). The SNP3 frequencies for
T/T, T/C and C/C genotypes in the low triglyceride groups
were 77.1 %, 18.8 % and 4.2 % respectively, and those in
the high triglyceride group were 59.1 %, 40.9 % and 0 %
respectively. The difference in genotype frequencies
between low and high triglyceride groups were significant
(p = 0.011) (Table 4).
No association between SNP3 and CAD
To investigate the relation of SNP3 polymorphism with
coronary artery disease we studied the association in all
subjects (those who are taking lipid lowering drugs are
included). There was no association between coronary
artery disease and SNP3 either in non diabetic subjects or
in type 2 diabetic patients (Table 5).
Discussion
Elevated serum lipid levels are an important risk factor for
atherosclerosis. Both environmental and genetic factors
contribute to variability in serum lipid levels [5]. In this
study, we choose the apo A-V gene as a genetic factor that
predispose to elevated triglyceride level. The dynamic
interfacial properties of apo A-V are consistent with the
hypothesis that apo A-V impedes triglyceride particle
assembly [7]. Thus, the effect of apo A-V on triglyceride
level can be attributed to the intracellularly function of
apo A-V to modulate hepatic VLDL synthesis and/or secre-
tion. Also apo A-V can lower plasma triglyceride by acti-
vating the lipoprotein lipase (LPL)[8]. In our study we
showed that SNP3 was significantly associated with
hypertriglyceridemia especially in type 2 diabetic patients.
This finding confirmed the idea that the effect of this SNP
on triglyceride metabolism was not influenced by ethnic
background [9]. However, it has been reported that the
major and minor allele frequencies differed between pop-
Table 3: Clinical Characteristics and lipid profile according to SNP3 of apo A-V in type 2 diabetic and in non diabetic subjects
Type 2 Diabetes Non Diabetes
Characteristics Genotypes
TT TC TT TC
Number 100 36 76 25
Sex (% men) 61 50 55.8 60
Smokers (%) 67.3 81.3 44.4 46.2
Age (years) 52.8 ± 7.6 54.8 ± 6.2 53.3 ± 8.8 51.5 ± 7.5
BMI (Kg/m2) 28.5 ± 4.3 28.7 ± 3.9 27.3 ± 3.0 28.1 ± 5.0
WHR 0.94 ± 0.06 0.93 ± 0.08 0.93 ± 0.08 0.9 ± 0.08
Cholesterol (mmol/l) 5.17 ± 1.15 5.17 ± 1.07 4.61 ± 1.32 4.53 ± 0.99
HDL-C (mmol/l) 0.90 ± 0.32 0.83 ± 0.34 0.92 ± 0.25 0.83 ± 0.26
Total TG (mmol/l) 2.05 ± 1.61 2.62 ± 1.59* 1.6 ± 1.42 1.75 ± 1.07
* significant difference between TT and TC genotypes (p = 0.016).
Table 4: Distribution of different apo A-V genotypes in type 2 diabetes between low and high triglyceride groups
Low triglyceride group ≤ 2.2 mmol/l High triglyceride group > 2.2 mmol/l
Polymorphism Number % Number %
T/T 74 77.1 26 59.1
T/C 18 18.8 18 40.9
C/C 4 4.2 nd nd
Total 96 100 44 100
nd : not detected
X2 = 8.962, p = 0.011, degree of freedom = 2.Page 3 of 6
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UK, Caucasian and Japanese respectively [10,3,9]. In our
population, the minor allele frequency (0.13) is almost
the same as in Caucasian [3] but lower than in Japanese
population [9]. However, the triglyceride level is higher in
Tunisian than in Japanese population. This paradoxical
observation confirms that triglyceride level is influenced
by environmental factors and other genetic factors (apo
CIII...).
In type 2 diabetes the triglyceride level is increased, which
is due to multiple factors related to insulin and carbohy-
drate metabolism, LPL activity, CETP activity... The
absence of an unusual allele frequency of SNP3 in type 2
diabetic patients compared to non diabetic subjects, in
spite of triglyceride level variation, shows that there is no
association between apo A-V SNP3 polymorphism and
the presence or absence of diabetes. Diabetic homozygous
for the major allele are more frequent in low triglyceride
group, showing that SNP3 is associated with triglyceride
variation in type 2 diabetic patients. Contrary to Esteve et
al., who have reported no significant difference in triglyc-
eride concentration with the apo A-V polymorphism in
type 2 diabetic patients [6], our results showed, then, that
SNP3 is associated with triglyceride level.
The relationship between SNP3 and coronary artery dis-
ease is under discussion. The LOCAT study showed that
there is no association between SNP3 and progression of
coronary heart disease [11]. Our results find no associa-
tion between SNP3 of apo A-V and development of coro-
nary artery disease either in diabetic patients or in non
diabetic subjects. This suggests that the high triglyceride
level in T/C genotype alone was not a good discriminator
of coronary heart disease. In contrast ; Szalai et al. showed
an association between SNP3 and an increased risk for
severe coronary artery disease [12]. Identifying genetic
and environmental factors that influence plasma lipid lev-
els represents a key step towards developing strategies for
preventing and treating CAD. Usually, in the case of type
2 diabetes, patients are taking lipid lowering drugs in
order to ameliorate their lipid profile, namely lower trig-
lyceride level and increase HDL-C concentration. Fibrates
represent a commonly used therapy for lowering plasma
triglyceride, its mechanism of action involves the activa-
tion of the nuclear receptor peroxisome proliferator acti-
vated receptor alpha (PPARα). The apo A-V is a highly
responsive PPAR  target gene [13]. While SNP3 is located
in promoter region, it should be interesting to study the
interaction between this polymorphism and lipid lower-
ing drugs response in different population.
Conclusion
In summary, the apo A-V SNP3 is associated with triglyc-
eride level in Tunisian type 2 diabetic patients. However,
this SNP is unlikely to be associated with the presence of
diabetes. Although SNP3 is associated with
hypertrigyceridemia, there was no relationship between
this polymorphism and coronary artery disease. Further
investigations were needed to determine the effect of
SNP3 on lipid lowering drug response.
Methods
Subjects
Three hundred and eight subjects, aged 45–70 years, par-
ticipated in this study. They belong to four groups. The
first group contained 74 type 2 diabetic patients with
CAD, among whom 12 are taking lipid lowering drugs.
The second group contained 78 type 2 diabetic patients
without CAD, all of them did not take lipid lowering
drugs. The third group contained 57 patients with CAD
and without diabetes, 70% of the patients are taking lipid
lowering drugs. The last group contained 99 controls
without diabetes nor CAD, 11 subjects are taking lipid
lowering drugs. The clinical and biological characteristics
of each group are summarized in Table 1.
All participants were recruited in the departments of inter-
nal medicine and cardiology in Monastir university hospi-
tal. Written or verbal informed consent were obtained
from all patients and controls before the study. All written
Table 5: Association between SNP3 of apo A-V and risk for coronary artery disease in diabetic and non diabetic subjects
Genotypes CAD- CAD +
Diabetes- T/T 74 (74.7) 41 (71.9) P = 0.514 OR = 1.29 (0.6–2.77)
T/C 21 (21.1) 15 (26.3)
C/C 4 (4.0) 1 (1.8)
Diabetes+ T/T 56 (71.8) 52 (70.3) P = 0.717 OR = 0.87 (0.41–1.83)
T/C 21 (26.9) 17 (23.0)
C/C 1 (1.3) 5 (6.7)
OR was calculated using T/T and T/C genotypes only.
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of eligible subjects in our study were illiterate. The diagno-
sis of diabetes was based on a previous history of diabetes
according to American Diabetes Association criteria [14].
The patients with CAD were defined as clinical history of
stable angina pectoris, previous acute coronary syn-
dromes with or without ST segment elevation. This CAD
was confirmed by coronary angiography. Exclusion crite-
ria were taking insulin, having a renal or liver failure or
thyroid disease, alcohol consumption before 3 days or
less, Body Mass Index (BMI) more than 35 Kg/m2 and gly-
cosylated hemoglobin (Hb A1c) more than 12%. Post
menopausal women had no hormone replacement ther-
apy. BMI was calculated using the formula : weight (Kg)/
height2 (m2). Obesity was defined as BMI>30 kg/m2.
Waist-to-hip ratio (WHR) was calculated from measure-
ments of the waist circumference taken at the mid point
between umbilicus and xiphoid and hip circumference, at
the widest point around the hips, respectively. Blood sam-
ples were drawn after subjects had fasted overnight (12
hours) into tubes containing EDTA. Plasma was immedi-
ately separated by centrifugation.
Laboratory Analysis
After DNA extraction, the single nucleotide polymor-
phism SNP3 within the apo A-V gene (-1311 T/C) was
determined by PCR-RFLP analysis using MseI restriction
endonuclease as described previously [3]. Plasma glucose,
glycosylated haemoglobin (HbA1c), lipids and lipopro-
teins were determined as described by Smaoui et al. [15].
Statistical Analyses
Data management and statistical analysis were performed
using SPSS 10.0 software. Results are summarized as
mean ± SD. Since triglyceride levels were not normally
distributed, logarithmic transformation of triglyceride
concentration was performed before the statistical analy-
sis. Student's test was used to compare continuous varia-
bles and Chi square (χ2) test was used to examine




BMI : Body Mass Index
CAD : Coronary Artery Disease
HDL : High Density Lipoproteins
HDL-C : HDL cholesterol
PCR-RFLP : Polymerase Chain Reaction-Restriction Frag-
ment Length Polymorphism
SNP : Single Nucleotide Polymorphism
TG : Triglyceride
VLDL : Very Low Density Lipoproteins
WHR : Waist-to-Hip Ratio
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